Combining Strattera and Buspar for ADHD with Comorbid Anxiety
Yes, atomoxetine (Strattera) can be safely combined with buspirone (Buspar) for patients with ADHD and comorbid anxiety disorders, though the evidence for added benefit over atomoxetine monotherapy is limited. The combination has been studied and shows acceptable tolerability, but only modest incremental efficacy gains 1.
Evidence for Combination Therapy
The primary evidence comes from a randomized controlled trial that directly tested this combination. In 241 adults with ADHD, atomoxetine plus buspirone showed statistically significant improvement over placebo at most time points, with an effect size of 0.51 versus 0.40 for atomoxetine alone 1. However, the combination was only statistically superior to atomoxetine monotherapy at week 4, with most other time points showing numerical but not significant advantages 1.
The more compelling approach is atomoxetine monotherapy for ADHD with comorbid anxiety, as atomoxetine itself has demonstrated efficacy for both conditions. The FDA label specifically notes that atomoxetine does not worsen anxiety in patients with ADHD and comorbid anxiety disorders 2. Multiple studies confirm atomoxetine reduces both ADHD and anxiety symptoms simultaneously 3, 4, 5, 6.
Dosing Recommendations
For Atomoxetine Monotherapy:
- Children/adolescents: Start 0.5 mg/kg/day, increase after minimum 3 days to target of 1.2 mg/kg/day (maximum 1.4 mg/kg/day or 100 mg, whichever is less)
- Adults: Start 40 mg/day, increase after minimum 3 days to target of 80 mg/day (maximum 100 mg/day)
If Adding Buspirone:
When combining with atomoxetine, buspirone dosing requires caution due to potential drug interactions. The FDA label for buspirone notes that when combining with other medications, start with low doses (2.5 mg twice daily) and titrate slowly based on clinical response 7. The combination trial used up to three times daily buspirone dosing 1.
Key Contraindications and Warnings
Atomoxetine-Specific:
- Black box warning for suicidal ideation - monitor closely, especially in first months and after dose changes 8
- Obtain cardiac history before initiation; perform ECG if risk factors present 8
- Monitor blood pressure and heart rate (atomoxetine increases both) 8
- Avoid in patients with narrow-angle glaucoma
- Dose reduction required for moderate/severe hepatic impairment 2
Buspirone-Specific:
- Absolute contraindication with MAOIs - risk of serotonin syndrome 7
- Multiple CYP3A4 interactions requiring dose adjustments 7
Combination Concerns:
While neither medication is primarily serotonergic, exercise caution when combining multiple agents that affect serotonin. The anxiety disorder guidelines warn about combining serotonergic drugs, though buspirone's partial agonist mechanism carries lower risk than full serotonergic agents 9.
Monitoring Protocol
Baseline:
- Personal and family cardiac history
- Blood pressure and heart rate
- Height and weight (for growth monitoring)
- Liver function tests
- Suicide risk assessment
Ongoing (every 1-2 weeks initially, then monthly):
- Blood pressure and heart rate at each visit
- Suicidal ideation screening, especially first 4 weeks
- ADHD symptom severity (standardized rating scales)
- Anxiety symptom severity (standardized rating scales)
- Adverse effects assessment
- Growth parameters every 3 months in children 8
Clinical Decision Algorithm
Step 1: For ADHD with comorbid anxiety, start with atomoxetine monotherapy as first-line treatment. Evidence shows atomoxetine effectively treats both conditions simultaneously 3, 4.
Step 2: Titrate atomoxetine to therapeutic dose over 2-4 weeks, monitoring for response in both ADHD and anxiety symptoms.
Step 3: If inadequate anxiety response after 8-12 weeks of optimized atomoxetine (when full effect is reached), consider:
- Adding CBT (combination therapy with CBT plus medication is superior to monotherapy for anxiety disorders) 9
- Adding an SSRI (stronger evidence base than buspirone for pediatric anxiety) 9
- Adding buspirone only if SSRIs are contraindicated or not tolerated
Step 4: If buspirone is added, start at 2.5 mg twice daily and increase slowly every 1-2 weeks based on tolerability, up to maximum 60 mg/day in divided doses.
Common Pitfalls to Avoid
- Don't assume combination is automatically better: The atomoxetine-buspirone trial showed only marginal benefits over monotherapy, with discontinuation rates of 15.5% versus 11.3% for atomoxetine alone 1
- Don't overlook atomoxetine's anxiolytic properties: Atomoxetine monotherapy significantly reduced anxiety in both pediatric and adult populations with comorbid anxiety disorders 2, 3, 4
- Don't rush titration: Rapid atomoxetine dose escalation causes more gastrointestinal side effects and somnolence 8
- Don't forget growth monitoring: Atomoxetine causes initial growth delays in first 1-2 years, though catch-up occurs by years 2-3 8
Tolerability Profile
The combination showed similar adverse event profiles to atomoxetine alone, with the most common being insomnia, nausea, dry mouth, headache, and asthenia. Dizziness was more frequent with the combination 1. Neither medication worsens tics in patients with comorbid tic disorders 2.